Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is on recovery track with 72.73% gain from a 1-year low price of $0.99. The company lost -6.56% to attain the price of $1.71 on 03/13/2018. Throughout the recent session, the prices were hovering between $1.65 and $1.82. These shares are 75.44% off its target price of $3 and the current market capitalization stands at $101.85M. The recent change has given its price a 2.69% lead over SMA 50 and -64.15% deficit over its 52-week high. The stock witnessed 22.14% gains, -37.82% declines and 44.3% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EKSO’s volatility during a week at 9.76% and during a month it has been found around 7.31%.Ekso Bionics Holdings, Inc. (EKSO) Top Holders
Institutional investors currently hold around $43 million or 39.2% in EKSO stock. Look at its top three institutional owners. Puissance Capital Management Lp owns $37.58 million in Ekso Bionics Holdings, Inc., which represents roughly 36.9% of the company’s market cap and approximately 87.39% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 1,302,696 shares of the stock are valued at $2.38 million. The third largest holder is Barclays Plc, which currently holds $512 thousand worth of this stock and that ownership represents nearly 0.5% of its market capitalization.
At the end of 12/31/2017 reporting period, 24 institutional holders increased their position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by some 21,578,135 shares, 14 decreased positions by 1,720,560 and 13 held positions by 182,702. That puts total institutional holdings at 23,481,397 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 20,743,790 shares while 9 institutional investors sold out their entire positions totaling 1,629,032 shares.Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Insider Trades
Multiple company employees have indulged in significant insider trading. Ekso Bionics Holdings, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President, EksoWorks Angold Russ has sold 50,000 shares of Ekso Bionics Holdings, Inc. (EKSO) in trading session dated Nov. 22, 2017. These shares are worth $175,500 and were traded at $3.51 each. The SEC filing shows that Peurach Jack performed a purchase of 20,000 shares. The Director added these shares by way of transaction on Sep. 14, 2017. The company’s shares were assimilated at $1.27 per share worth to an investment of some $25,400 on account of Peurach Jack.
Director, Wendell Amy Mcbride, purchased 16,264 common shares of Ekso Bionics Holdings, Inc. (EKSO) in the open market. In a transaction dated Sep. 14, 2017, the shares were bought at an average price of $1.23, giving away a sum of $20,005. After this purchase, 16,264 common shares of EKSO are directly owned by the insider, with total stake valued at $27,811.
In the transaction dated Sep. 08, 2017, the great number of shares acquired came courtesy the President & CEO; Looby Thomas added a total of 15,000 shares at an average price of $1.13, amounting to approximately $16,950. The insider now directly owns 20,315 shares worth $34,739.Ekso Bionics Holdings, Inc. (EKSO) Analyst Guide
Not many analysts have released their opinion on Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.